|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||62.33 - 62.93|
|52-week range||58.29 - 66.80|
|PE ratio (TTM)||39.96|
|Earnings date||27 Oct 2017|
|Dividend & yield||1.88 (3.00%)|
|1y target est||69.95|
Jim Cramer sat down with Joe Papa, the new CEO of the controversial Valeant Pharmaceuticals, to catch up on the drugmaker's turnaround.
Activists have been working behind the scenes since January.
Two of President Donald Trump's business councils unraveled on Wednesday, following a series of defections by chief executives over Mr. Trump's comments about the violence in Charlottesville, Va. Here ...